Kozin et al., 2019 - Google Patents
The convergence of Alzheimer's disease pathogenesis conceptsKozin et al., 2019
View PDF- Document ID
- 1132315890580158826
- Author
- Kozin S
- Makarov A
- Publication year
- Publication venue
- Molecular Biology
External Links
Snippet
Advances in the research of molecular factors involved in the onset and progression of Alzheimer's disease, have led to the creation of several pathogenesis concepts of the most common neurodegenerative disease in the world, and amyloid, cholinergic, and …
- 206010001897 Alzheimer's disease 0 title abstract description 100
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kozin et al. | The convergence of Alzheimer’s disease pathogenesis concepts | |
| Gao et al. | Tau in Alzheimer's disease: mechanisms and therapeutic strategies | |
| Folch et al. | Memantine for the treatment of dementia: a review on its current and future applications | |
| Folch et al. | Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein | |
| Liu et al. | Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy | |
| Lashuel et al. | The many faces of α-synuclein: from structure and toxicity to therapeutic target | |
| Walsh et al. | A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration | |
| Thal et al. | Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease | |
| Cai et al. | Roles of AMP-activated protein kinase in Alzheimer’s disease | |
| Brettschneider et al. | Spreading of pathology in neurodegenerative diseases: a focus on human studies | |
| Goure et al. | Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics | |
| Peng et al. | Current and future therapeutic strategies for Alzheimer’s disease: An overview of drug development bottlenecks | |
| O'Neill et al. | Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease | |
| RU2496502C2 (en) | Method of preventing and treating neurodegenerative diseases | |
| Coughlin et al. | Emerging diagnostic and therapeutic strategies for tauopathies | |
| Cisbani et al. | Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls | |
| Qi et al. | Intraventricular infusion of clusterin ameliorated cognition and pathology in Tg6799 model of Alzheimer’s disease | |
| Wang et al. | Intramuscular delivery of p75 NTR ectodomain by an AAV vector attenuates cognitive deficits and Alzheimer's disease‐like pathologies in APP/PS 1 transgenic mice | |
| Ettcheto et al. | Peripheral and central effects of memantine in a mixed preclinical mice model of obesity and familial Alzheimer’s disease | |
| Zhang et al. | Secondary chemical bonding between insoluble calcium oxalate and carbonyl oxygen atoms of GLY and VAL residues triggers the formation of Aβ aggregates and their deposition in the brain | |
| Gholami | Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches | |
| Santiago-Mujika et al. | Tubulin and tubulin posttranslational modifications in Alzheimer’s disease and vascular dementia | |
| Kakoty et al. | Brain insulin resistance linked Alzheimer’s and Parkinson’s disease pathology: an undying implication of epigenetic and autophagy modulation | |
| Hung et al. | Modulating metals as a therapeutic strategy for Alzheimer’s disease | |
| Ma et al. | Reduction of NF-κB (p65) in scrapie-infected cultured cells and in the brains of scrapie-infected rodents |